NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
NRx Pharmaceuticals welcomes President Trump's Executive Order aimed at accelerating the development and approval of psychedelic medications for treating serious mental illnesses such as depression, PTSD, and suicidality. The company’s drug candidate NRX-100 has received FDA Fast Track designation and anticipates submitting a New Drug Application w…